Program
aflutinib
Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.
Drug pageAflutinib: every studyMany companies study it; this page follows only the 21 they lead. All 63 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allist Pharmaceuticalsits history only | 114 open or running | phase 3since Apr 12, 2021 | Nov 21, 2016 | Dec 2026phase 3 · NCT04853342 |
| Beijing Aosaikang Pharmaceuticalits history only | 41 open or running | phase 3since Oct 12, 2019 | Apr 10, 2018 | none ahead |
| ArriVent BioPharmaits history only | 33 open or running | phase 3since Oct 31, 2022 | Apr 6, 2022 | Feb 2029phase 3 · NCT07185997 |
| Abbisko Caymanits history only | 11 open or running | phase 2since Oct 30, 2024 | Oct 30, 2024 | Dec 30, 2027phase 2 · NCT06668103 |
| Alphamab Oncologyits history only | 11 open or running | phase 1since Mar 5, 2025 | Mar 5, 2025 | Jun 30, 2028phase 1 · NCT06868732 |
| MediLink Therapeutics (Suzhou)its history only | 11 open or running | phase 2since Sep 3, 2025 | Sep 3, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Nov 21, 2016.
- Apr 20, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT04360915 · 24 enrolled · China
- Apr 12, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04858958 · 90 enrolled · China
- Apr 12, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342 · 318 planned · China
- Jul 5, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04958967 · China
- Apr 6, 2022ArriVent BioPharma’s first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to ArriVent BioPharmaArriVent BioPharma · NCT05364073 · 160 enrolled · United States, Australia, Canada and more
- Jul 14, 2022Phase 2 study in NSCLCAllist Pharmaceuticals · NCT05466149 · 100 enrolled · China
- Oct 31, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT05607550 · 398 enrolled · United States, Australia, Brazil and more
- Nov 11, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
- Oct 30, 2024Abbisko Cayman’s first study: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNew to Abbisko CaymanAbbisko Cayman · NCT06668103 · 54 planned · China
- Mar 5, 2025Alphamab Oncology’s first study: phase 1 study in Advanced Non-small Cell Lung CancerNew to Alphamab OncologyAlphamab Oncology · NCT06868732 · 288 planned · China
- Apr 9, 2025Phase 3 study in NSCLC Patients With Brain MetastasisAllist Pharmaceuticals · NCT06970639 · 380 planned · China
- May 20, 2025Phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419 · 338 planned · China
- Aug 15, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT07185997 · 480 planned · United States, Australia, Canada and more
- Sep 3, 2025MediLink Therapeutics (Suzhou)’s first study: phase 2 study in Breast NeoplasmsNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT07169994 · 414 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342
- Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationAbbisko Cayman · NCT06668103
- Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT06868732
- Oct 31, 2028Primary completion: phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419
TargetBeta
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07169994Breast Neoplasms · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Sep 1, 2026 | 414 |
| NCT07185997Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 3 | Recruiting | ArriVent BioPharma | Feb 2029 | 480 |
| NCT07010419NSCLC · China | 3 | Recruiting | Allist Pharmaceuticals | Oct 31, 2028 | 338 |
| NCT06970639NSCLC Patients With Brain Metastasis · China | 3 | Recruiting | Allist Pharmaceuticals | Mar 2029 | 380 |
| NCT06868732Advanced Non-small Cell Lung Cancer · China | 1 | Recruiting | Alphamab Oncology | Jun 30, 2028 | 288 |
| NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China | 2 | Recruiting | Abbisko Cayman | Dec 30, 2027 | 54 |
| NCT05631678Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Aug 3, 2022 | 48 |
| NCT05607550Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | ArriVent BioPharma | Oct 6, 2026 | 398 |
| NCT05466149NSCLC · China | 2 | Active, not recruiting | Allist Pharmaceuticals | Jun 27, 2025 | 100 |
| NCT05364073Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 1 | Active, not recruiting | ArriVent BioPharma | Jun 3, 2025 | 160 |
| NCT04958967NSCLC · China | 1 | Withdrawn | Allist Pharmaceuticals | May 1, 2022 | 0 |
| NCT04858958NSCLC · China | 1 | Completed | Allist Pharmaceuticals | Dec 5, 2024 | 90 |
| NCT04853342Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Allist Pharmaceuticals | Dec 2026 | 318 |
| NCT04360915Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Dec 30, 2019 | 24 |
| NCT04143607Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Mar 31, 2024 | 337 |
| NCT03941340Healthy Male Volunteers · China | 1 | Completed | Allist Pharmaceuticals | Sep 6, 2019 | 6 |
| NCT03926182Healthy Male Volunteers · China | 1 | Completed | Allist Pharmaceuticals | Apr 3, 2019 | 16 |
| NCT03502850Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Beijing Aosaikang Pharmaceutical | Jan 2021 | 507 |
| NCT03452592Advanced NSCLC Patients With T790M · China | 2 | Terminated | Allist Pharmaceuticals | Apr 21, 2021 | 220 |
| NCT03127449Advanced NSCLC · China | – | Terminated | Allist Pharmaceuticals | May 12, 2021 | 116 |
| NCT02973763NSCLC | 1 | Terminated | Allist Pharmaceuticals | Feb 4, 2021 | 14 |
How it is read
Names in the registry
- “Furmonertinib”, 6 entries
- “Alflutinib”, 3 entries
- “ASK120067”, 3 entries
- “Firmonertinib”, 2 entries
- “Furmonertinib 160mg”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasm Metastasis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.